BioLargo’s CupriDyne Technology Shown Capable of Complete SARS-CoV-2 Inactivation in 10 Minutes

WESTMINSTER, CA / ACCESSWIRE / September 2, 2020 /  BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced an important milestone in its ongoing efforts to bring to market a safe and effective antiviral disinfectant based on its patented CupriDyne® technology. In a third-party study conducted by researchers at the Galveston National Laboratory (GNL) at the University of Texas Medical Branch (UTMB), a modified CupriDyne formula was shown to cause complete inactivation of SARS-CoV-2 (the COVID-19 virus) in 10 minutes – roughly the same performance observed with highly concentrated bleach.

BioLargo had previously disclosed that its CupriDyne technology was proven capable of reducing SARS-CoV-2 titers by 99% after 30 minutes, with complete inactivation occurring after 60 minutes of CupriDyne exposure. Since that time, BioLargo scientists worked to modify the CupriDyne formula to achieve faster bacterial and viral inactivation in order to prepare to file for an EPA registration for a new disinfecting product (to be named) that is based on the CupriDyne technology. These new results indicate that those efforts were successful, and that the technology is now capable of total antiviral disinfection in 10 minutes against SARS-CoV-2.

BioLargo President & CEO Dennis P. Calvert commented, “We believe that the future is bright for our CupriDyne-based disinfectants. We intend to apply for registration with the EPA once product designs are finalized. It is important to understand that we are achieving these extraordinary results at a significantly lower concentration than that of bleach in the same test protocol. We have retained a leading EPA consulting firm to lead us in the EPA registration process and intend to move ahead as soon as possible. These products are a great addition to our expanding portfolio.”

Taxonomy

• Covid-19